Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Bausch Health Companies Inc. logo

NYSE · BHC

Bausch Health Companies Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$8.20

Down-$0.71 (-7.97%)

Updated Nov 1, 2026, 7:13 PM

SID Score

7.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.6B
P/E ratio
7.19
Dividend yield
0.00%
52-week range
$4.33 – $9.04
Volume
8.87M
Avg. volume
2.36M

Price performance · BHC

BHC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BHC closed at $8.20 after 20 trading sessions, up 39.22% for the selected period.

Last close
$8.20
Period change
+39.22%
Period low
$5.89
Period high
$8.91
Daily close
View OHLC price history
BHC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.93$9.04$8.175$8.208.87M
Oct 29, 2026$7.66$9.04$7.58$8.9133.78M
Oct 28, 2026$6.29$6.97$6.25$6.928.07M
Oct 27, 2026$6.37$6.37$6.225$6.311.56M
Oct 26, 2026$6.53$6.55$6.27$6.352.4M
Oct 23, 2026$6.44$6.49$6.2012$6.442.43M
Oct 22, 2026$6.43$6.505$6.405$6.491.2M
Oct 21, 2026$6.40$6.515$6.29$6.452.03M
Oct 20, 2026$6.42$6.54$6.36$6.422.03M
Oct 19, 2026$6.27$6.42$6.25$6.321.35M
Oct 16, 2026$6.35$6.385$6.20$6.302.19M
Oct 15, 2026$5.95$6.35$5.95$6.312.31M
Oct 14, 2026$5.89$6.05$5.85$5.891.75M
Oct 13, 2026$5.91$5.92$5.732$5.891.56M
Oct 12, 2026$6.27$6.345$5.77$5.932.54M
Oct 9, 2026$6.05$6.17$6.015$6.041.04M
Oct 8, 2026$6.14$6.1995$6.02$6.041.27M
Oct 7, 2026$6.04$6.33$6.02$6.152.01M
Oct 6, 2026$5.94$6.105$5.825$6.023.05M
Oct 5, 2026$5.73$5.96$5.71$5.891.47M

Latest BHC news

The latest Smart Investors Daily articles mentioning BHC.

Stock researchCompany · Overview

BHC research

Overview

Company profile and research snapshot.

Company profile

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
BHC recent ratings
DateFirmRatingTarget
Aug 4, 2026TD COWENHold—
May 1, 2026TRUIST SECURITIESHold—
Apr 30, 2026TRUIST SECURITIESHold—
Apr 30, 2026TD COWENHold—
Apr 29, 2026TD COWENHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Bausch Health Canada Announces Expanded Public Reimbursement for (Pr)OKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia

Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced expanded public reimbursement for PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg, with coverage now available for eligible patients, subject to the applicable reimbursement criteria, through public drug plans in seven provinces and multiple federal drug plans.

Yahoo · Oct 12, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduat

Yahoo · Oct 12, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By